Cancer Vaccine by Fusions of Dendritic and Cancer Cells

Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells repr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & developmental immunology 2009-01, Vol.2009 (2009), p.1-13
Main Authors: Koido, Shigeo, Hara, Eiichi, Homma, Sadamu, Namiki, Yoshihisa, Ohkusa, Toshifumi, Gong, Jianlin, Tajiri, Hisao
Format: Article
Language:English
Subjects:
Animals
Antigen Presentation
Cancer
Cancer Vaccines
Cell Differentiation
Cell Fusion - methods
Cell Fusion - trends
Clinical Trials as Topic
Cytotoxicity, Immunologic
Dendritic Cells - immunology
Dendritic Cells - metabolism
Dendritic Cells - pathology
Humans
Immune system
Immunology
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Proteins
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination.
ISSN:1740-2522
2314-8861
1740-2530
2314-7156
DOI:10.1155/2009/657369